Honokiol inhibits U87MG human glioblastoma cell invasion through endothelial cells by regulating membrane permeability and the epithelial-mesenchymal transition

Introduction

Gliomas are the most common brain tumors of the adult central nervous system. Astrocytomas, which are tumors composed predominantly of neoplastic astrocytes, account for 80–85% of all gliomas (1). Grade IV astrocytomas, also referred to as glioblastoma multiforme (GBM), is the most common primary malignant brain cancer (2). The proliferation rates of GBM are two to five times higher than grade III tumors, and patients with GBM have a dismal prognosis, with a median survival time of less than 15 months despite aggressive therapy (3). A characteristic of GBM is its ability to infiltrate and invade the surrounding normal brain tissue. Despite advances in techniques for administering radiotherapy, local recurrence of glioblastomas typically leads to patient mortality. Thus, therapies that effectively target invasive glioma cells may significantly improve clinical outcomes.

The underlying molecular mechanisms of brain tumor invasion are complex and involve integrated biochemical processes requiring a coordinated effort of intracellular and extracellular interactions (1). For effective invasion, tumor cells must first detach from the nascent tumor mass and invade the surrounding stroma, which is composed of parenchymal cells and the extracellular matrix (ECM). Cell surface adhesion molecules play an important role in the interaction between the cells and ECM. Cell adhesion molecules (CAMs) are expressed on a variety of cells, including vascular endothelial cells (ECs) and tumor cells (4–7), that have been activated by cytokines such as IL-1α, IL-6 or TNF-α (8,9). Specifically, TNF-α induces the upregulation of intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in ECs (10,11). ICAM-1 and VCAM-1 have been shown to be involved in cell-cell and cell-ECM interactions and are mechanistically important for the extravasation of cancer cells during metastasis (12,13).

Cadherins are important molecules involved in tumor progression. Different cadherins, including E-cadherin, N-cadherin, T- (or H-) cadherin and VE-cadherin, are reported to have different functions and are expressed in different tissues. E- and N-cadherin are the most thoroughly studied cadherins in terms of the EMT process; the loss of E-cadherin expression in epithelial tumors is associated with a more invasive phenotype and metastasis (14). N-cadherin has been shown to promote cell motility and migration, the opposite effect to that of E-cadherin (14). VE-cadherin is an endothelium-specific member of the cadherin family of adhesion proteins and regulates transmembrane endothelial adherens junctions. Thus, cadherins, including E-cadherin, N-cadherin and VE-cadherin, are involved in tumor metastasis.

Honokiol is a well-known bioactive constituent of the bark of Magnolia officinalis and has been reported to prevent and protect the brain from damage (15) as well as to exert antitumor efficacy in vitro and in vivo (16–19). Notably, treatment with honokiol may be a potential strategy to overcome immunoresistance in glioma (20), as honokiol can cross the BBB and the BCSFB (21). In addition, our previous study demonstrated that honokiol induces apoptotic cell death through the upregulation of the Bax/Bcl-2 ratio and inhibits invasion through the regulation of ICAM-1 and VCAM-1 in human glioblastoma T98G cells (22). Based on these results, honokiol may represent an effective drug for the treatment of brain tumors, specifically glioblastoma. In this study, we were interested in the effect of honokiol on glioblastoma invasion. Thus, we investigated whether honokiol affects glioblastoma invasion through the regulation of adhesion molecules and VE-cadherin as well as the EMT process in U87MG, a commonly studied grade IV glioma cell line that has been analyzed in at least 1,700 publications over four decades (23).

Materials and methods

Materials

Honokiol (Fig. 1A) was supplied by Wako Chemical (Wako, Japan). Anti-VCAM-1, anti-VE-cadherin, anti-Snail, anti-N-cadherin, anti-β-catenin and anti-E-cadherin antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phospho-VE-cadherin (phospho-Y658) antibody was purchased from Abcam (Cambridge, MA, USA). Enhanced chemiluminescence (ECL) western blotting detection reagent was obtained from Amersham (Buckinghamshire, UK). All other chemicals, including Evans blue dye, were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Figure 1. The effect of honokiol on the viability of U87MG cells and BMECs. (B and C) Cells were treated with the indicated concentrations of honokiol for 24 h. Cell viability was determined by the MTT assay. All data represent mean values ± SEM of three independent experiments in a triplicate assay. Significant compared with control, **P<0.01.

Cell culture

Human glioblastoma cells (U87MGs) and mouse brain microvascular endothelial cells (BMECs) were purchased from ATCC and grown in DMEM medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 IU/ml penicillin and 10 μg/ml streptomycin and incubated in a humidified 5% CO2 incubator.

Cell viability assay

Cell viability was determined colorimetrically using a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were plated at 1×104 cells per well in 24-well plates. After drug treatments, MTT solution was added to each well (0.1 mg/well) and incubated for 4 h. Supernatants were removed, and formazan crystals in the wells were dissolved in 200 μl of dimethyl sulfoxide for 30 min at 37°C and the optical density at 570 nm was measured using a microplate reader (Bio-Rad, Hercules, CA, USA).

Western blot analysis

Cells were lysed using PRO-PREP protein extraction solution. Aliquots of 40 μg of protein were subjected to 10% SDS-polyacrylamide gel electrophoresis. Separated proteins in SDS-polyacrylamide gel were transferred onto Hybond-P+ polyvinylidene difluoride membranes (Amersham Biosciences UK Ltd.). The membrane was blocked with 5% non-fat milk in Tris-buffered saline containing 0.05% Tween-20 (TBS-T) for 2 h at room temperature and the membranes were incubated with the indicated primary antibodies. Proteins were detected with ECL western blotting detection reagent according to the manufacturer’s instructions.

Fractionation of cell extracts

The cellular compartment was extracted as previously described with a minor modification (11). Briefly, cells were washed with ice-cold phosphate-buffered saline (PBS; pH 7.4) and lysed in buffer A (10 mM HEPES, pH 8.0, 1.5 mM MgCl2, 0.5 mM dithiothreitol and 1X protease inhibitors). The supernatant (cytoplasmic extract) was obtained by centrifugation at 10,000 × g for 15 min. The pellets were washed once with buffer A and resuspended in buffer B (10 mM Tris-Cl, pH 7.5, 0.5% deoxycholate, EDTA, 0.5 mM, 0.5 mM dithiothreitol, and 1% Nonidet P-40). The suspension was agitated for 30 min at 4°C and centrifuged at 10,000 × g for 20 min. The supernatant fraction containing nuclear proteins was collected.

Adhesion assay

BMECs were treated with honokiol for 24 h and subsequently stimulated with TNF-α for 6 h. Thereafter, U87MG 1×106 cells were added to BMEC layers. After 30 min, cell suspensions were removed, and BMECs were gently washed with DMEM medium. The cells were counted under a light microscope, and images were taken using an Olympus microscope (CKX41) equipped with a camera (Nikon, DS-U3).

Matrigel invasion assay

The Matrigel invasion assays were performed in two ways. First, the insert wells (8-μm pore size, BD Falcon, Franklinlakes, NJ, USA) were coated with 100 μl of Matrigel (1 mg/ml, BD Falcon), and BMECs were then added (2×105 cells per well). After 2 h, U87MG cells (2×105) that had been pretreated with honokiol for 24 h were added to the BMEC layers on Matrigel in the inserts. The inserts were incubated for 24 h in a 37°C cell culture incubator. In the second method, BMECs were pretreated with honokiol for 24 h and then washed with PBS three times. After BMECs were stimulated with TNF-α for 6 h, U87MG cells were added to BMEC-Matrigel coated wells and incubated for 24 h. The non-invasive cells that remained on the upper side of the insert were removed. The cells on the lower part of insert membranes were stained with 4′,6-diamidino-2-phenylindole (DAPI) and counted under a light microscope.

Membrane permeability study

Cell culture inserts (0.4-μm pore size, BD Falcon) were placed in a 24-well plate. BMECs were seeded on the inserts and treated with honokiol for 1 h. The cells were washed with PBS and treated with TNF-α. Four hours later, the media were removed, the cells were washed with PBS and 100 μl of 200 μg/ml Evans blue suspended in 0.1% bovine serum albumin in transport buffer (10 mM HEPES, 132 mM NaCl, 4 mM KCl, 1.4 mM MgCl2, 1.2 mM H3PO4, 1 mM CaCl2, 4.5% glucose, pH 7.4) was added to the upper chamber (insert wells). After 4 h, aliquots (100 μl) were collected from the lower chamber (24-well plate). Molecular permeability across the membrane was determined by measuring optical density of Evans blue at 620 nm using an EIA reading photometer (US.HL 5500P0, Bio-Rad).

Statistical analysis

Scanning densitometry was performed using Image Master® VDS (Pharmacia Biotech Inc., San Francisco, CA, USA). All results are representative of three independent experiments performed in triplicate (mean ± SEM). Significant differences within data were evaluated by one-way analysis of variance (ANOVA) and the post hoc test by Scheffe. P-values <0.05 were treated as statistically significant.

Results

The effect of honokiol on the cell viability of U87MG human glioblastoma cells and BMECs

In this study, we aimed to investigate the effect of honokiol on the cell invasion process of U87MG human glioblastoma cells through brain microvascular endothelial cells (BMECs) and its possible mechanisms. Thus, first, we examined the cell viability of U87MG cells and BMECs in response to honokiol in a lower range compared to the previous study (22). When U87MG cells and BMECs were treated with indicated honokiol (1–20 μM) for 24 h, the results revealed that honokiol significantly decreased the cell viability of U87MG only at doses of 20 μM (Fig. 1B). BMECs exhibited significant reduction in viability at concentrations of 10 μM and 20 μM (Fig. 1C). Honokiol-mediated cytotoxicity was not significant at doses <20 μM in U87MGs or 10 μM in BMECs. The IC50 of honokiol in U87MG and BMECs was 22.66 and 13.09 μM, respectively.

Honokiol inhibited VCAM-1 expression by TNF-α in BMECs and suppressed the adhesion of U87MG cells to TNF-α-stimulated BMECs

Cell-cell and cell-ECM interactions are partially regulated by adhesion molecules. Specifically, VCAM-1 has been shown to be important in cancer cell metastasis (24,25). Accordingly, we examined whether honokiol inhibits VCAM-1 expression by TNF-α in BMECs. BMECs exhibited a significant induction of VCAM-1 protein levels in response to TNF-α (10 ng/ml, 6 h), which was efficiently inhibited by pretreatment with honokiol; significant inhibition occurred at 5–20 μM honokiol (Fig. 2A). Next, we investigated the effect of honokiol on U87MG adhesion to BMECs. Adhesion of U87MG cells to BMECs stimulated with TNF-α at 10 ng/ml for 6 h was dramatically increased compared to unactivated BMECs. In contrast, treatment of the BMECs with 5-20 μM honokiol for 24 h before TNF-α stimulation resulted in a significant reduction of adhesion of U87MG cells to ECs (Fig. 2B and C).

Figure 2. Honokiol inhibits VCAM-1 expression by TNF-α in BMECs as well as U87MG cell adhesion to TNF-α-treated BMECs. (A) BMECs were cultured with honokiol for 24 h and then stimulated with TNF-α (10 ng/ml) for 6 h. The expression of VCAM-1 and β-actin was analyzed by western blot analysis. (B and C) After BMECs were pretreated with honokiol for 24 h, the cells were activated with TNF-α for 6 h. Subsequently, U87MG cells were added to the BMECs for 30 min. The remaining cell suspension was withdrawn and the number of adherent cells was quantified under a light microscope. All data represent mean values ± SEM of three independent experiments in a triplicate assay. Significant compared to the control, **P<0.01; significant compared to TNF-α, ##P<0.01.

Honokiol reduces TNF-α-mediated phosphorylation of VE-cadherin and increases membrane permeability in BMECs

Tyrosine phosphorylation of VE-cadherin is known to be associated with weak junctions and impaired barrier function. Therefore, we investigated the effect of honokiol on the phosphorylation of VE-cadherin at tyrosine residue 658 (Y658) by western blotting. When BMECs were treated with TNF-α in a time-dependent manner, TNF-α was able to prominently increase phospho-VE-cadherin at 4 h (preliminary data, not shown). Thus, we measured the phospho-VE-cadherin levels at 4 h after TNF-α treatment. Honokiol treatment 1 h prior to TNF-α significantly decreased TNF-α-induced phospho-VE-cadherin at very low dose (1 μM) (Fig. 3A). This result coincided with the membrane permeability results. The concentration of Evans blue dye across BMECs increased with TNF-α treatment and significantly decreased with honokiol treatment (1–20 μM). TNF-α-induced membrane permeability was significantly reduced with 20 μM of honokiol, however, the permeability remained slightly higher than with 10 μM of honokiol, possibly due to cell toxicity caused by 20 μM honokiol (Fig. 3B).

Figure 3. Honokiol inhibits TNF-α-mediated phosphorylation of VE-cadherin and reduces membrane permeability in BMECs. (A) BMECs were pre-treated with honokiol for 1 h, followed by incubation with TNF-α for 4 h. VE-cadherin expression and phosphorylation of VE-cadherin (Y658) were determined by western blot analysis. (B) BMECs were seeded on the inserts. The cells were treated as described in (A). After treatment, Evans blue was added to the upper chamber of the inserts. Four hours later, aliquots were sampled from the lower chamber and the optical density (OD) was measured at 620 nm. Data represent the mean values ± SEM of four independent experiments. Significant compared to the control; **P<0.01, significant compared with TNF-α, #P<0.05; ##P<0.01.

Honokiol inhibits EMT in U87MG cells via downregulation of the mesenchymal markers Snail, β-catenin and N-cadherin and the upregulation of the epithelial marker E-cadherin

Then, we assessed whether honokiol regulates EMT proteins, including Snail, β-catenin, N-cadherin and E-cadherin. Honokiol effectively reduced the mesenchymal markers Snail, β-catenin and N-cadherin but increased the levels of the epithelial marker E-cadherin. These results suggest that honokiol suppresses EMT by downregulating the mesenchymal markers Snail, β-catenin and N-cadherin and upregulating the epithelial marker E-cadherin (Fig. 4).

Figure 4. Honokiol downregulates the mesenchymal markers Snail, β-catenin and N-cadherin but upregulates the epithelial marker E-cadherin. U87MG cells were treated with honokiol for 24 h, and the levels of Snail (A) and β-catenin (C) in nuclear fractions and the E-cadherin (B) and N-cadherin (D) levels in cytosolic fractions were determined by western blot analysis. Data are presented as the mean values ± SEM of three independent experiments. Significant compared to the control, *P<0.05; **P<0.01.

Honokiol effectively inhibits U87MG invasion through BMECs

We evaluated the effect of honokiol on human glioblastoma invasion through BMECs using two different methods. First, to test the effect of honokiol on U87MG invasion through the regulation of EMT, U87MG cells were treated with honokiol in a dose-dependent manner and added to BMECs that were not treated with honokiol or TNF-α (Fig. 5A). In our second method, BMECs were treated with honokiol and stimulated with TNF-α and incubated with U87MG cells that were not treated with honokiol to examine the effect of honokiol on U87MG invasion through the regulation of VCAM-1 and membrane permeability in BMECs (Fig. 5D). As expected, U87MG cells treated with honokiol exhibited reduced invasion through BMECs (Fig. 5B and C). In addition, treatment of BMECs with honokiol suppressed U87MG cell invasion through TNF-α-stimulated BMECs (Fig. 5E and F).

Figure 5. Honokiol inhibits the invasion of human glioblastoma U87MG cells through BMECs. (A–C) BMECs were added to the Matrigel coated insert wells. U87MG cells were pretreated with honokiol for 24 h, harvested and added onto BMECs as described in Materials and methods. (D–F) BMECS that had been treated with honokiol for 24 h were added to Matrigel coated inserts wells. After 2 h, U87MG cells were added to BMEC-Matrigel coated inserts. The inserts were incubated for 24 h in a 37°C cell culture incubator. The non-invasive cells that remained on the upper side of the insert were removed and the cells on the lower part of insert membranes were stained with DAPI and counted under a fluorescence microscope. Values represent the means ± SEM of 3 independent experiments (significant compared to the control, **P<0.01).

Discussion

Glioblastoma is almost uniformly fatal with only a few patients surviving longer than 2 years (26). Two major problems impede the success of chemotherapy. First, the delivery of sufficient amounts of most antineoplastic drugs into brain tissue is prevented by the BBB. Second, high-grade gliomas are often characterized by high intrinsic chemoresistance. Honokiol is reported to cross the BBB and the BCSFB and to overcome immunoresistance in glioma, strongly suggesting that it could be an effective drug for the treatment of brain tumors, including glioblastoma. Our previous study demonstrated that honokiol induced apoptotic cell death and inhibited cell invasion through regulation of ICAM-1 and VCAM-1 in human glioblastoma T98G cells (22). Recently, it was reported that tumors, including gliomas, contain a small subpopulation of cancer stem cells (CSCs). These cells are characterized by their ability to form neural spheres, antibiotic resistance and high cell migration ability (27). According to Moon and Park (28), U87MG cells formed neural spheres and expressed CD133 and Bmil, which are the canonical cell surface markers of brain CSCs, at much higher levels than any other glioblastomas (A172, T98G, U138, U251, U373). Given these characteristics of U87MG, finding new treatments that can target this cell type may be beneficial in developing an effective cure for glioblastoma. Therefore, we further investigated the effect of honokiol on U87MG human glioblastoma cell invasion and the possible mechanisms underlying this regulation by honokiol. Our results revealed that honokiol effectively inhibited the adhesion of U87MG cells to BMECs by inhibiting normal VCAM-1 expression. Honokiol also perturbed U87MG invasion through BMECs by inhibiting VCAM-1 expression and suppressing phospho-VE-cadherin-mediated BMEC permeability. TNF-α-induced permeability of BMECs was significantly reduced by 1 μM honokiol; however, permeability appeared to increase slightly at 20 μM, possibly due to the cytotoxicity of honokiol at 20 μM.

As mentioned above, glioblastoma exhibits aggressive proliferation and highly invasive properties and can diffusely infiltrate various regions of the normal brain, accounting for a poor prognosis. Tumor invasion results from vasculature leakiness and the directional migration of tumor cells across a disrupted endothelium; thus, cancer metastasis requires communication between tumor cells and ECs that culminates in the disruption of EC-EC contacts and the degradation of the vascular basement membrane. Cell surface adhesion molecules play an important role in the interaction between the cells and ECM, and some highly metastatic human melanoma cells adhere and migrate to VCAM-1 rather than ICAM-1 (24). In addition, endothelial permeability is a major factor influencing intravasation, extravasation and invasion in cancer metastasis. Endothelial cells possess several molecular mechanisms by which vascular permeability can be modulated. Such mechanisms focus on adherens junction organization, and in several cases, target VE-cadherin specifically. Furthermore, the phosphorylation, cleavage and internalization of VE-cadherin are thought to affect endothelial permeability (29). In this study, honokiol inhibited U87MG cell invasion across ECs through the downregulation of VCAM-1 expression and the inhibition of phospho-VE-cadherin-mediated EC permeability.

In addition, loss of E-cadherin expression in epithelial tumors is associated with a more invasive phenotype and metastasis (14). N-cadherin has been shown to promote cell motility and migration, an effect opposite to that of E-cadherin (14). The cadherin switch may occur during the transition from a benign to an invasive, malignant tumor phenotype. All gliomas, regardless of grade, lack E-cadherin expression (1). Concerning the upstream signals that affect N- and E-cadherin, Snail suppresses transcription of E-cadherin, and β-catenin induces N-cadherin expression. Snail and β-catenin are negatively regulated by GSK-3β, which is regulated by intracellular signaling pathways including PI3K/Akt. In other words, activation of PI3K/Akt results in the phosphorylation of GSK-3β (inactivation of GSK-3β), which in turn increases Snail and β-catenin protein levels. In this study, honokiol significantly reduced N-cadherin levels but increased E-cadherin levels in cytosolic fractions. In addition, honokiol decreased both Snail and β-catenin levels in nuclear fractions. These results suggest that honokiol suppresses EMT through the reduction of both Snail and β-catenin levels, which results in the suppression of N-cadherin and the induction of E-cadherin. Further study is needed to examine whether honokiol may decrease the phosphorylation of Akt while increasing the phosphorylation of GSK-3β.

Taken together, our findings suggest that honokiol exhibits an inhibitory effect on the process of metastasis by targeting the interaction between U87MG and BMECs; honokiol regulates the adhesion of U87MG cells to BMECs by inhibiting VCAM-1 expression in BMECs, and reduces the invasion of U87MG cells through BMECs by reducing BMEC permeability and inhibiting EMT in U87MG. These findings suggest that honokiol may serve as a therapeutic strategy against brain tumors such as glioblastoma.

Abbreviations:

Acknowledgements

This study was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A1A3003268) and by the MRC program of MOST/KOSEF (NRF-2005-0049415).

References